Nektar Therapeutics 

€1.24
37
+€0.03+2.73% Tuesday 07:02

Statistik

Harga Tertinggi Hari Ini
1.24
Harga Terendah Hari Ini
1.24
52M Tinggi
-
52M Rendah
-
Volume
0
Rata-Rata Volume
-
Kap Pasar
235.62M
Rasio P/E
-
Hasil Dividen
-
Dividen
-

Mendatang

Pendapatan

6NovDiharapkan
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Berikutnya
-0.45
-0.36
-0.27
-0.19
EPS yang Diharapkan
-0.200971
EPS Aktual
T/A

Orang Juga Mengikuti

Daftar ini didasarkan pada daftar pantauan orang-orang di Stock Events yang mengikuti ITH.F. Ini bukan rekomendasi investasi.

Peserta

Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.

Peringkat Analis

4Rata-Rata Target Harga
Perkiraan tertinggi adalah €4.
Dari 1 peringkat dalam 6 bulan terakhir. Ini bukan rekomendasi investasi.
Beli
100%
Tahan
0%
Jual
0%

Tentang

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. Howard W. Robin
Karyawan
137
Negara
US
ISIN
US6402681083
WKN
000165417

Daftar